What is the catalog number for Crizotinib-d5?

The catalog number for Crizotinib-d5 is HY-50878S.

What sizes are available for Crizotinib-d5?

Crizotinib-d5 is available in the following size(s): 1 mg.

Is Crizotinib-d5 in stock?

Crizotinib-d5 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Crizotinib-d5?

Crizotinib-d5 is manufactured by QuantiMol.

What is the estimated delivery time for Crizotinib-d5?

Estimated delivery time for Crizotinib-d5 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Crizotinib-d5?

The safety data sheet for Crizotinib-d5 is available here: http://file.medchemexpress.com/batch_PDF/HY-50878S/Crizotinib-d5-SDS-MedChemExpress.pdf.

Crizotinib-d5

Crizotinib-d5 is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].

Product Specifications

CAS Number

1395950-84-1

Product Name Alternative

PF-02341066-d5

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

Anaplastic lymphoma kinase (ALK) ; Autophagy; c-Met/HGFR; ROS Kinase

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Purity

99.7

Solubility

DMSO : 20mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 0.1mg/mL (ultrasonic)

Smiles

NC1=C(C=C(C=N1)C2=CN(N=C2)C3(C([2H])(CNCC3([2H])[2H])[2H])[2H])O[C@H](C)C4=C(C=CC(F)=C4Cl)Cl

Molecular Formula

C21H17D5Cl2FN5O

Molecular Weight

455.37

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75 (21) :4548-59.|[3]Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7 (349) :ra102.|[4]Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11 (8) :996-1006.|[5]Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8 (3) :354-369.|[6]Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) . J Med Chem. 2011 Sep 22;54 (18) :6342-63.|[7]Cullinane C, et al. Differential (18) F-FDG and 3'-deoxy-3'- (18) F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52 (8) :1261-7|[8]Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6 (12 Pt 1), 3314-3322.|[9]Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67 (9), 4408-4417.